Target- |
Mechanism- |
|
|
|
Inactive Indication- |
Drug Highest PhasePhase 1 |
First Approval Ctry. / Loc.- |
First Approval Date- |
/ Not yet recruitingPhase 1 A Phase 1, Placebo-controlled, Randomized, Observer-blind Study to Describe the Safety, Tolerability and Immunogenicity of SCB-1019T in Adults Who Were Vaccinated With AREXVY at Least 18 Months Before
CLO-SCB-1019-002 is the first study of SCB-1019T vaccine for revaccination in older adults who were previously vaccinated with AREXVY. The safety, tolerability and immunogenicity of SCB-1019T are assessed.
100 Clinical Results associated with Clover Biopharmaceuticals USA, Inc.
0 Patents (Medical) associated with Clover Biopharmaceuticals USA, Inc.
100 Deals associated with Clover Biopharmaceuticals USA, Inc.
100 Translational Medicine associated with Clover Biopharmaceuticals USA, Inc.